Acerus is a Canadian-based pharmaceutical company focused on the commercialization and development of innovative pharmaceutical products that improve the patient experience.
Founded in 2008, Acerus has grown into a fully integrated specialty pharmaceutical company with expertise in all stages of the pharmaceutical product life-cycle. The company is focused on Men’s Health (Urology and Andrology).
Acerus’ foundational product Is NATESTO®, a testosterone therapy based on our patented nasal gel technology. NATESTO® is approved in the United States, Canada and South Korea for the treatment of adult males diagnosed with hypogonadism.
Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP) and the OTCQB Exchange (OTCQB: ASPCF).